Local

Blood test for prostate cancer screening more effective, study says

A blood test to check for prostate cancer may be better than experts initially thought, especially in black men, according to a new study. There is no standard test for prostate cancer, according to the US Centers for Disease Control and Prevention. Two of the most commonly used tests are a digital rectal test and a blood test for prostate-specific antigen (PSA), an enzyme that is usually higher in men with prostate cancer. A study published Sunday in the New England Journal of Medicine Evidence looked at how successful blood tests were for all races, and in particular for black men, by estimating how often these tests led to overdiagnosis and hyperthermia. The researchers looked at records from three decades to 2016, last year’s records were available. Not only was the test more effective than scientists initially thought, the study found that the net benefit was even better for black men than for the general population. Death was prevented for every 11 to 14 men of all races diagnosed with cancer, the study says. Among black men, the test prevented 1 death for every 8 to 12 men diagnosed and 1 death for every 5 to 9 men treated for prostate cancer. Previous studies have found that tests prevented 1 death for every 23 men diagnosed and this led to over-treatment. Prostate cancer is ubiquitous. With the rise of testing in the late 1980s, there was a trend toward treating tumors that were not as real a threat as they were, according to the American Society of Clinical Oncology. But more recently, for tumors that are not at risk for progression, doctors have adopted a more proactive monitoring approach. Prostate cancer is the second leading cause of cancer death in American men, after lung cancer, according to the American Cancer Society. Out of every 100 American men, about 3 will develop prostate cancer in their lifetime, according to the CDC, and 2 or 3 men will die from prostate cancer. Black men are almost twice as likely to die from prostate cancer as the general population. They also get prostate cancer more often. However, black men have historically been underrepresented in clinical trials examining the success rate of tests and other diagnostic tools. “for black men,” the study concluded. “The possibility of overdiagnosis and hyperthermia remains, although these lesions can be mitigated with modern protocols for measuring men before biopsy and active monitoring for men at low risk.” The study is partly funded by the Bristol Myers Squibb Foundation, which has prostate anti-cancer drugs in development.Dr. William Dahut, chief scientist for the American Cancer Society, said the findings were “very important. This is not something I actually say.” He did not participate in the investigation. However, Dahut noted that some practices are a little different now than when these files were compiled. Doctors can also check for prostate cancer with an MRI scan, for example, and a cancer diagnosis does not lead to treatment as often. It used to be called “waiting alertness”, but Dahut said it was actually more active than it sounds. Depending on a person’s risk of the cancer spreading, they may be closely monitored by regular MRI scans and biopsies instead of receiving treatments such as surgery and radiation. They will have an ongoing discussion with their doctor about how to manage the disease. “” These days, you have a much greater ability to make a more subtle and thoughtful decision with your doctor about whether or not to seek treatment for prostate cancer. ” “Ultimately,” he added, “what does it mean, if you find a disease and treat it properly, the results can really be affected in a significant and positive way.”

A blood test to check for prostate cancer may be better than experts initially thought, especially in black men, according to a new study.

There is no standard test for prostate cancer, according to US Centers for Disease Control and Prevention. Two of the most commonly used tests are a digital rectal test and a blood test for prostate-specific antigen (PSA), an enzyme that is usually higher in men with prostate cancer.

A study published Sunday in New England Journal of Medicine Evidence examined how successful the blood tests were for all races, and in particular for black men, calculating how often these tests led to overdiagnosis and hyperthermia. The researchers looked at records from three decades to 2016, while last year’s records were available.

Not only was the test more effective From what scientists initially believed, the study found that the net benefit is even better for black men than for the general population.

One death was prevented for every 11 to 14 men of all races diagnosed with cancer, the study says. Among black men, the test prevented 1 death for every 8 to 12 men diagnosed and 1 death for every 5 to 9 men treated for prostate cancer.

Previous studies have found that tests prevented 1 death for every 23 men diagnosed and this resulted in over-treatment.

Prostate cancer is omnipresent. With the rise of testing in the late 1980s, there was a trend toward treating tumors that were not as real a threat as they were, according to American Society of Clinical Oncology. But more recently, for tumors that do not pose a risk of progression, doctors have increasingly adopted an active surveillance approach.

Prostate cancer is the second leading cause of death from cancer in American men, behind lung cancer, according to American Cancer Society. Out of every 100 American men, about 3 will develop prostate cancer in their lifetime, according to the CDC, and 2 or 3 men will die from prostate cancer.

Black men are almost twice as likely to die from prostate cancer as the general population. They also get prostate cancer more often. However, black men are historically underrepresented in clinical trials examining the success rate of tests and other diagnostic tools.

“These data should prompt policymakers to reconsider the usefulness of PSA-based prostate cancer screening, especially for black men,” the study concluded. “The potential for overdiagnosis and hyperthermia remains, although these lesions can be mitigated with modern protocols for screening men before biopsy and active surveillance for men at low risk.”

The study is partly funded by the Bristol Myers Squibb Foundation, which is developing drugs for prostate cancer.

Dr. William Dahut, a lead scientist for the American Cancer Society, said the findings were “very important. This is not something I actually actually say.” He did not participate in the investigation.

However, Dahut noted that some practices are a little different now than when these files were compiled. Doctors can also check for prostate cancer with an MRI scan, for example, and diagnosing cancer does not lead to treatment as often.

This was called “careful waiting”, but Dahut said it was actually more active than it sounds.

Depending on a person’s risk of spreading cancer, they can be closely monitored by regular MRI scans and biopsies instead of receiving treatments such as surgery and radiation. They will have an ongoing conversation with their doctor about how to manage the disease.

“This study should really encourage more people to get screened,” Dahut said. “These days, you have a lot more opportunities to make a more subtle and thoughtful decision with your doctor about whether or not you will be treated for prostate cancer.

“Ultimately,” he added, “it means that if you diagnose the disease and treat it properly, the results can really be affected in a significant and positive way.”

Blood test for prostate cancer screening more effective, study says Source link Blood test for prostate cancer screening more effective, study says

Related Articles

Back to top button